TETRA BIO-PHARMA INC Stock News

Tetra Bio-Pharma Inc (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery, has announced that its investigational new drug ARDS-003 studied in a viral-infected organoid

Combining ARDS-003 with antiviral drugs significantly decreased viral replication compared to antiviral treatment alone . OTTAWA, ON, June 21, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the

Biopharmaceutical company with a pipeline of novel proprietary drugs Partnership with medicinal chemistry biotech to ensure new proprietary molecules for long term success Target markets: coronavirus

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) said that Health Canada has accepted its New Drug Submission (NDS) for REDUVO and has formally entered the final phase in the drug review proces

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) said that Health Canada has accepted its New Drug Submission (NDS) for REDUVO™  and has formally entered the final phase in the drug review p

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 The Com

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced multiple clinical advancements, including the dosing of the first patient in its REBORN1 trial of QIXLEEF as a treatment for cancer pa

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced that Echelon Wealth Partners Inc and a syndicate of underwriters have fully exercised the overallotment option on the company's previo

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) said it was proposing to nominate two additional directors at its upcoming annual and special meeting of shareholders scheduled for May 28, 2021 as the com

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) closed its previously announced bought-deal public offering raising C$10 million. The offering consisted of 25 million units priced at $0.40 per unit and l

Tetra Bio-Pharma Inc (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) said it is speeding up its “revolutionary” Phase 2 clinical trial, PLENITUDE, to evaluate the safety and effectiveness of its investigationa

Tetra Bio-Pharma Inc. (CVE:TBP) said it has entered into an agreement with a syndicate led by Echelon Wealth Partners Inc. under which the underwriters have agreed to purchase 25 million units from t

12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, has announced the start of the REBORN1 clinical trial.  The trial is designed

First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 6, 202